Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by BAULD, H.W.
Right arrow Articles by BROWN, S.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BAULD, H.W.
Right arrow Articles by BROWN, S.S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, 1974, Vol. 46, No. 4 273-281
© 1974 The Board of Management and Trustees of the British Journal of Anaesthesia

other

AETIOLOGY OF PROLONGED APNOEA AFTER SUXAMETHONIUM

H.W. BAULD, P.F. GIBSON, P.J. JEBSON and S.S. BROWN

Forty-seven patients demonstrating prolonged apnoea after suxamethonium have been investigated in a 3-year survey carried out in south-east Scotland. Clinical information, and serrum cholinesterase studies using a new substrate, succinyldithiocholine, provide evidence on the aetiology of suxamethonium hypersensitivity. While 13 Patients possessed only variant forms of the serum enzyme, the remaining 34 patients appeared to have a catalytically active form of cholinesterase. The causes of prolonged apnoca in the latter group are discussed. The value of screening the relatives of patients with cholinesterase variants is demonstrated by the finding of 26 relatives "at risk" out of 123 screened.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
N. Lindegardh, G. R. Davies, T. T. Hien, J. Farrar, P. Singhasivanon, N. P. J. Day, and N. J. White
Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases.
Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3197 - 3199.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
M. P. Goetz, M. M. Ames, and R. M. Weinshilboum
Primer on Medical Genomics Part XII: Pharmacogenomics--General Principles With Cancer as a Model
Mayo Clin. Proc., March 1, 2004; 79(3): 376 - 384.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
T. Yen, B. N. Nightingale, J. C. Burns, D. R. Sullivan, and P. M. Stewart
Butyrylcholinesterase (BCHE) Genotyping for Post-Succinylcholine Apnea in an Australian Population
Clin. Chem., August 1, 2003; 49(8): 1297 - 1308.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
C. Cerf, M. Mesguish, I. Gabriel, S. Amselem, and P. Duvaldestin
Screening Patients with Prolonged Neuromuscular Blockade After Succinylcholine and Mivacurium
Anesth. Analg., February 1, 2002; 94(2): 461 - 466.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.